Reference

Last reviewed: 29 Apr 2026
Sources cited: 10

Compound class711.86 Da

Selective growth hormone secretagogue (GHRP) — pentapeptide

5-residue synthetic peptide containing unnatural amino acids (Aib, D-2-Nal, D-Phe) and C-terminal amidation. Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂. The standard 3-letter sequence parser only handles natural L-amino acids, hence the fallback.

Ipamorelin

Last verified: 2026-04-29

At a glance


Also known as	NNC 26-0161 (developmental code)
Class	Selective growth hormone secretagogue (GHRP) — pentapeptide ghrelin-receptor agonist
Typical route	Subcutaneous injection, once or twice daily
Half-life	~2 hours (terminal); GH pulse peaks ~40 min post-dose; full clearance 6–8 hours1 2
Molecular weight	711.86 Da
Sequence / structure	Aib-His-D-2-Nal-D-Phe-Lys-NH₂ (5 residues; the unnatural amino acids and C-terminal amidation are stability modifications, not natural fragments)
UK status	Not approved. Not available through any UK licensed pharmacy. Sold as a research chemical, like most peptides in this encyclopedia.
US status	Removed from FDA Category 2 in September 2024; reviewed at the October 2024 PCAC meeting; Category 1 reclassification reportedly imminent following the February 2026 HHS announcement, but not formally published as of April 2026.8

What it is

Ipamorelin is a synthetic five-amino-acid peptide that triggers a short, natural-shaped pulse of growth hormone release. It was developed in the late 1990s by Novo Nordisk as the first selective growth hormone secretagogue — meaning it stimulates GH release without meaningfully raising cortisol, prolactin, or ACTH, which the older GHRPs (GHRP-2, GHRP-6, hexarelin) all do at therapeutic doses.1

That selectivity is the entire reason ipamorelin matters in the biohacker space. If you want the metabolic and recovery effects of pulsatile GH without the stress-hormone collateral that older GHRPs produce, ipamorelin is the cleanest tool currently available. The trade-off is that the per-pulse GH release is somewhat smaller than what GHRP-2 produces, which is why ipamorelin is almost always paired with a GHRH analogue (CJC-1295, sermorelin, or tesamorelin) rather than run alone.

It is not human growth hormone. It does not replace GH; it asks your pituitary to release more of its own. This matters for two reasons: the GH pulse it produces is shaped like a natural pulse rather than a flat exogenous dose, and the response decays as the pituitary’s stored GH depletes — so doubling the dose doesn’t double the response indefinitely.

Mechanism

Ipamorelin is an agonist of the growth hormone secretagogue receptor type 1a (GHSR-1a) — the same receptor ghrelin uses. When it binds, the receptor activates Gq/11 signalling, which drives intracellular calcium release in pituitary somatotrophs and triggers GH exocytosis. A secondary Gs-coupled cAMP/PKA pathway potentiates the response.5

Three mechanistic features distinguish ipamorelin from older GHRPs:

Selectivity for the somatotrophic axis. At doses up to 200× the GH ED50, ipamorelin produces no significant cortisol, prolactin, or ACTH elevation. GHRP-2 and GHRP-6 both raise cortisol meaningfully at therapeutic doses. This is the basis for the “clean GHRP” framing.1
Pulsatile release matching circadian rhythm. GH concentration peaks ~40 minutes post-injection and returns to baseline by 6 hours, mimicking the natural ultradian GH pulse pattern rather than producing the sustained elevation that exogenous HGH delivers.1
Synergy with GHRH analogues. GHSR-1a agonism (ipamorelin) and GHRH receptor agonism (CJC-1295, sermorelin, tesamorelin) act on different receptors with different intracellular pathways. Co-administration produces 3–5× higher GH release than either compound alone at the same dose.3

The mechanism that drives the synergy is also the reason ipamorelin requires fasted dosing: elevated insulin and glucose suppress somatotroph response. Eating a carbohydrate-containing meal in the hour before injection blunts the GH pulse substantially. This is why standard practice is bedtime dosing 2–3 hours after the last meal.

Routes of administration

Subcutaneous injection (the standard route)


Bioavailability	Acceptable; sufficient to drive a measurable GH pulse
Onset	GH pulse peaks ~40 minutes post-dose
Duration	GH elevation 2–4 hours; full clearance 6–8 hours
Typical dose (this route)	100–300 mcg per injection, 1–2× daily
Equipment	Insulin syringe (29G–31G, U-100), bacteriostatic water, alcohol wipes
When this route makes sense	Default and standard. Most community protocols and the published clinical trial used subQ.

The bedtime injection is the dominant pattern: it aligns with the body’s natural night-time GH pulse, requires the least dietary discipline (most users have already finished eating), and the GH-driven recovery effects overlap with sleep.

Intramuscular injection


Bioavailability	Comparable to subQ; absorption faster
Onset	Slightly faster than subQ (peak earlier)
Duration	Same total elimination window
Typical dose (this route)	Same as subQ (no dose adjustment needed)
When this route makes sense	Rarely chosen; subQ is easier and equally effective for GH pulse outcomes.

IM is mechanically possible but offers no clear advantage over subQ for ipamorelin. Most users default to subQ; IM appears mostly in cross-route community discussion rather than as a typical practice.

Intranasal


Bioavailability	Substantially lower than subQ; absorption is variable across studies
Onset	Slower and more variable
Duration	Per-dose effect smaller and less reliable than injection
Typical dose (this route)	Not standardised in community use
When this route makes sense	Theoretical interest only. Not a viable alternative to subQ for serious protocols.

The nasal route was studied in early pharmacokinetic work but absorption is too variable to recommend for users who care about consistent GH pulse output.6

Oral

Not viable. Ipamorelin is GI-degraded.

Cross-route comparison

SubQ at bedtime is the standard. IM is mechanically equivalent but practically unused. Intranasal and oral are not real options. The route question for ipamorelin is not which to choose; it’s whether your timing (fasted, evening) and stack pairing (with a GHRH analogue) are right.

What the evidence says

Honest summary: the foundational pharmacology is well-characterised, but the clinical program failed at its only major indication and the compound has essentially no long-term human safety data.

Pharmacokinetics and selectivity (well-supported)

The core pharmacology is documented in published, peer-reviewed work from Novo Nordisk’s original development program: dose-proportional kinetics, ~2-hour terminal half-life, GH selectivity at therapeutic doses, no meaningful cortisol/prolactin/ACTH elevation. These are the strongest claims that can be made about the compound.1 2

Phase 2 postoperative ileus trial (failed; development discontinued)

The only meaningful Phase 2 program for ipamorelin was Helsinn Therapeutics’ 2014 trial in postoperative ileus following bowel resection. 117 patients, IV ipamorelin 0.03 mg/kg twice daily vs. placebo, no significant difference in time to first tolerated meal (25.3 hours ipamorelin vs 32.6 hours placebo, p=0.15). Helsinn discontinued development.7

This matters editorially. The most-completed clinical program for ipamorelin failed for the indication it was designed for, and no further Phase 2 or Phase 3 program has been brought forward by any sponsor. Community use rests on the underlying pharmacology and on extrapolation from short GH-pulse measurements, not on outcomes data.

What the evidence does NOT show

No long-term human safety data. The longest controlled human dosing in published trials is ~7 days. Multi-month or multi-year safety in healthy users is unknown.
No outcome trials in healthy biohacker populations. No study has measured body composition, recovery, sleep, or any of the outcomes biohackers actually use ipamorelin for.
No head-to-head comparison with HGH or with other secretagogues at clinically relevant durations.
No data on receptor desensitisation with chronic use, which is why the community 5-on/2-off cycling pattern exists — it’s defensive, not evidence-based.

The community use case for ipamorelin is mechanistically plausible (the peptide does what it says: it triggers a clean GH pulse) but the downstream claims about body composition, recovery, sleep depth, and longevity rest on inference from GH biology generally, not on trials of ipamorelin specifically.

Typical use patterns

Stack with a GHRH analogue (the dominant pattern)

Ipamorelin is rarely used alone. The standard practice is to pair it with a GHRH analogue — most commonly CJC-1295 (no DAC), sometimes sermorelin, occasionally tesamorelin. The synergy is real (3–5× GH release vs. either alone) and the pharmacology supports it: GHSR-1a + GHRH receptor agonism activate non-overlapping pathways.3

Typical bedtime stack:

Ipamorelin: 200–300 mcg
CJC-1295 (no DAC): 100–300 mcg
Same syringe, same injection
2–3 hours after the last meal
1× daily, usually before bed

Twice-daily protocols (morning fasted + evening fasted) exist but are less common because mornings are harder to keep fasted and the bedtime pulse is the higher-leverage one.

Cycling

The community pattern is 5 days on, 2 days off weekly, plus longer cycles of 3–6 months on, 1–2 months off. The reasoning is theoretical receptor-desensitisation prevention rather than data-driven. There is no published evidence on whether continuous ipamorelin loses efficacy, but the cycling convention is widely adopted as a precaution.

Duration

Cycles of 8–12 weeks for most users; longer (6+ months) in users running ipamorelin as a sustained recovery or sleep-quality intervention rather than a body-composition push.

Stacking beyond GHRH analogues

BPC-157 / TB-500: common pairing for users running ipamorelin during a recovery / orthopaedic phase. No documented interactions.
NAD+ precursors (NMN, NR), MOTS-c: common in longevity-focused stacks. No documented interactions.
Other GHRPs (GHRP-2, GHRP-6, hexarelin): redundant — same receptor — and the older GHRPs cancel ipamorelin’s selectivity advantage by adding cortisol/prolactin elevation.
HGH: users who already have prescription HGH access do not benefit from adding ipamorelin; the secretagogue route is for users who don’t.

For sensitive systems

Ipamorelin is one of the better-tolerated peptides in this encyclopedia for the sensitive-systems audience, primarily because of its GHRP selectivity. The standard sensitive-population concerns — cortisol elevation, immune-axis disruption, mast-cell-relevant histamine activity — are minimised by ipamorelin’s pharmacology rather than just by gentle dosing.

That said, GH-axis stimulation has its own profile and the sensitive-systems framing is not “this is harmless”; it’s “the failure modes are different from BPC-157 or KPV.”

Start dose for sensitive users. 100 mcg subQ at bedtime, paired with 100 mcg CJC-1295 (no DAC). Hold for 1–2 weeks before considering an increase. The community-standard 200–300 mcg dose is a reasonable target but not a starting point for users with reactive nervous or immune systems.

Ramp. If tolerated, increase to 200 mcg ipamorelin / 200 mcg CJC after 1–2 weeks. Most sensitive users find 200 mcg sufficient; the move from 200 to 300 mcg is a smaller felt-effect step than the jump from 100 to 200.

Expected adjustment profile:

Mild headache in the first few days of dosing — most likely vasoactive, related to GH-driven fluid shifts. Usually resolves within a week.
Tingling, numbness, or carpal-tunnel-like sensations in the hands or wrists — fluid retention pressing on peripheral nerves. Dose-dependent. If it appears, drop the dose; it reverses within days.
Mild flushing or warmth at injection — usually local, transient.
Vivid dreaming in the first 1–2 weeks — common with GH-pulse compounds, generally welcomed but worth flagging.
Hunger spike the morning after dosing — ipamorelin shares the ghrelin-receptor mechanism that drives appetite. Usually mild and tolerable; for users tracking appetite for other reasons (GLP-1 stack, eating-disorder history) this is worth knowing.

What’s not normal and warrants stopping: sustained headache, persistent paraesthesia that doesn’t reverse on dose reduction, blood pressure elevation, joint pain that wasn’t there at baseline. These are uncommon but real signals that the GH-driven fluid/IGF-1 effects are too aggressive for the user’s physiology.

For MCAS / histamine-sensitive users. No specific histamine activity documented. Lower mast-cell concern than BPC-157 or thymosin-alpha-1; the receptor target (GHSR-1a) is not directly mast-cell-relevant.

For POTS users. Mild fluid retention is plausible at standard doses. Monitor for worsening orthostatic symptoms in the first 2 weeks; if present, the dose is too high. Beta-blockers and standard POTS management are not affected by ipamorelin.

For UARS / chronic fatigue / ME/CFS. This is a population where ipamorelin’s sleep-architecture effects matter most. Improved deep-sleep duration is the most consistent community report and the most defensible mechanistically (GH pulse depth correlates with slow-wave sleep). Some users find the GH-driven recovery effects genuinely helpful; others find the morning hunger spike or carpal-tunnel-like sensations more disruptive than the sleep benefit is worth. Worth a 4-week trial, not a long commitment up front.

For active or recent cancer history. Relative contraindication. GH-axis stimulation may theoretically promote growth of GH/IGF-1-responsive tumours. There is no specific human evidence either way for ipamorelin, but the mechanism makes a cautious posture appropriate. Wait until clear of treatment with oncology guidance before considering.

Interactions worth considering:

HGH: redundant; do not stack.
Other GHRPs: redundant and remove the selectivity advantage.
Insulin / metformin / GLP-1 agonists: GH transiently raises blood glucose. In well-controlled users this is usually subclinical; in active diabetic management it can affect titration. Worth flagging to a prescriber if relevant.
Steroids: exogenous corticosteroids blunt GH pulse response; ipamorelin will be less effective during a steroid course.
SSRIs, SNRIs, LDN, beta-blockers: no documented interactions.

Reasonable expectations

Onset. Most users notice improved sleep quality (deeper, more vivid dreams, easier wake-ups) within the first 1–2 weeks. Body composition changes — modest fat loss, slight lean mass support, improved recovery between training sessions — appear over 6–12 weeks if at all.

Response rate. Sleep-quality improvement is the most consistently-reported subjective effect; the rough community signal is that ~70% of users report a clear sleep change. Body-composition response is more variable and harder to attribute given that most users adjust training and diet alongside.

What the evidence actually supports.

GH pulse on demand — strongly supported by published PK/PD work.
Selectivity for GH over cortisol/prolactin/ACTH — strongly supported.
Sleep architecture changes — plausible mechanistically (GH and slow-wave sleep correlate); not directly studied for ipamorelin.

What the evidence does not support.

Body composition outcomes at any specific magnitude — no controlled trial measured this.
Anti-ageing or longevity outcomes — entirely speculative for this compound.
“Restored youthful GH levels” — the marketing framing some clinics use. Ipamorelin produces GH pulses; whether those pulses restore anything specifically is not characterised.

What not to expect.

HGH-equivalent effects. Ipamorelin produces a GH pulse; HGH delivers a sustained elevation. The body-composition and recovery effects of HGH at therapeutic doses are larger and faster than what ipamorelin can produce.
Effect without the stack. Ipamorelin alone is real but small. The community standard of pairing with a GHRH analogue is there because the synergy meaningfully increases the pulse magnitude.
Effect without fasted dosing. Eating before injection blunts the response substantially. A “dose at any time of day” protocol will produce a fraction of the GH pulse a fasted bedtime dose produces.

Cost

Ipamorelin is not available through licensed UK pharmacy channels as of April 2026. There is no NHS or private-prescription pricing to quote.

On the grey market (research-chemical supply, sold “for research use only / not for human consumption”):

5 mg vials are the most common research-chem size; sometimes 10 mg
Approximate per-vial pricing in the UK research-chem market: £25–60 depending on vendor and quantity
Combined “ipamorelin + CJC-1295 (no DAC)” blend vials are widely sold; ~£35–80 per blended vial

Monthly cost at standard doses (research-chem, vendor-neutral estimate):

200 mcg ipamorelin daily, 5 days/week: roughly 4 mg / month → ~£25–60/month for ipamorelin alone
Stacked with CJC-1295 at 200 mcg daily, 5 days/week: roughly £40–100/month total

These are economics figures, not vendor recommendations. Quality varies by vendor and the lab-test transparency of any given research-chem source is the more important variable than price.

Sensitive-start economics. A user starting at 100 mcg/day uses half the compound, which means a 5 mg vial covers ~50 doses — about 2.5 months at 5-on/2-off cycling. This is the most cost-efficient starting position regardless of audience.

Reconstitution

This section covers reconstitution of research-chemical ipamorelin. There is no licensed pen or prefilled product for ipamorelin in any major jurisdiction; everyone using ipamorelin outside a clinical trial is reconstituting lyophilised powder.

What’s in the box

Research-chemical ipamorelin ships as lyophilised white powder in a glass vial, typically 5 mg or 10 mg per vial. The vial is sealed with a rubber stopper and aluminium crimp.

You’ll also need:

Bacteriostatic water (BAC water) — sterile water with 0.9% benzyl alcohol. Required for the standard ~28-day stability window.
Insulin syringe (U-100) — typically 1 mL with 29G–31G needle. 100 units = 1 mL, so each unit = 0.01 mL.
A larger syringe (3 mL or 5 mL) for transferring BAC water into the vial.
Alcohol wipes, a clean working surface, and somewhere to record what you did.

The math

Ipamorelin is dosed in micrograms rather than milligrams (200 mcg = 0.2 mg), so reconstitution needs to put the typical dose at a readable mark on a U-100 syringe. The community-standard reconstitution is 5 mg vial + 2 mL BAC water → 2.5 mg/mL, which gives clean unit math.

5 mg vial, 2 mL BAC water (the standard)

Concentration: 2.5 mg/mL (2,500 mcg/mL)
100 mcg = 0.04 mL = 4 units (right at the readability floor — consider 1 mL BAC for sensitive-start dosing)
200 mcg = 0.08 mL = 8 units
300 mcg = 0.12 mL = 12 units

5 mg vial, 1 mL BAC water (for sensitive-start / low-dose users)

Concentration: 5 mg/mL (5,000 mcg/mL)
100 mcg = 0.02 mL = 2 units (below readability floor; not recommended)
This dilution is less appropriate for low doses, not more — counterintuitively, more BAC water makes small doses easier to read.

5 mg vial, 2.5 mL BAC water (for very low / sensitive-start dosing)

Concentration: 2 mg/mL (2,000 mcg/mL)
50 mcg = 0.025 mL = 2.5 units (still below the readability floor; consider 5 mL BAC if you really want 50 mcg accuracy)
100 mcg = 0.05 mL = 5 units (right at the floor)
200 mcg = 0.1 mL = 10 units

Stacked with CJC-1295. The standard practice is a single combined vial (often pre-blended by the vendor) or two separately reconstituted vials drawn into the same syringe. If reconstituting separately at 2.5 mg/mL each: 200 mcg ipamorelin + 200 mcg CJC = 8 units + 8 units = 16 units total in one bedtime injection.

The Peptrax Vial Plan calculator handles the same math interactively — enter your vial size, BAC volume, and dose, and it returns draw volume and doses per vial.

Reconstitution procedure

Wipe the rubber stopper of the lyophilised vial and the BAC water vial with alcohol.
Draw the chosen volume of BAC water into the larger syringe.
Insert the needle into the lyophilised vial at an angle, with the tip touching the inside wall above the powder. Inject the water slowly down the inside of the vial, not directly onto the powder. Forcing water onto lyophilised peptide can denature it.
Leave the vial undisturbed for 1–2 minutes. Do not shake. Gently swirl if needed; the powder dissolves on its own.
Once the solution is clear, label the vial: compound, concentration, reconstitution date.
Store refrigerated (2–8°C / 36–46°F).

Some practitioners pass the reconstituted solution through a 0.22 µm syringe filter as a belt-and-braces sterility step. With a sealed lyophilised vial and clean technique, this is optional rather than standard.

Storage and stability

Ipamorelin reconstituted with BAC water is stable for roughly 4 weeks refrigerated, with the same conservative/middle/optimistic spread as other research-chem peptides:

Conservative: 14–21 days refrigerated
Middle: 28 days refrigerated (the most commonly cited figure)
Optimistic: ~30 days

The honest middle is 28 days at 2–8°C. Store at the back of the refrigerator where temperature is most stable. Do not freeze.

If you reconstitute with plain sterile water instead of BAC water, the vial is single-use — discard within 24 hours.

For a 5 mg vial dosed at 200 mcg/day, 5 days/week: 25 doses → 5 weeks of theoretical doses, just over the 4-week stability window. Most users finish a vial well within shelf life. Sensitive-start users at 100 mcg/day get 50 doses → 10 weeks of theoretical doses but only 4 weeks of stable solution; plan for some product loss or buy smaller vials if available.

Areas of concern ⚠

The evidence gap

Ipamorelin’s foundational pharmacology is published and peer-reviewed; the downstream claims about body composition, sleep, recovery, and longevity rest on inference, not direct evidence. The compound’s only completed Phase 2 trial failed for its target indication and development was discontinued. Community use is reasonable mechanistically but is not supported by outcome data the way licensed GLP-1 agonists are.

For a sceptical reader: ipamorelin produces a GH pulse, that’s well-documented. Whether that GH pulse meaningfully changes anything you care about over a 12-week protocol is genuinely an open question.7

Long-term safety is uncharacterised

The longest controlled human dosing in published trials is approximately one week. Multi-month or multi-year safety in healthy users is unknown. The mechanistic concerns extrapolated from GH biology are:

IGF-1 elevation — sustained GH pulses raise IGF-1, which is broadly anabolic but has theoretical implications for GH/IGF-1-responsive tumour growth (see below).
Insulin sensitivity — GH transiently antagonises insulin. Whether multi-month ipamorelin use shifts insulin sensitivity in healthy users is not characterised.
Pituitary feedback — chronic GHSR-1a stimulation may downregulate receptors over months. The community 5-on/2-off cycling pattern is a precaution against this, not a fix supported by data.

Cancer / tumour-growth concern

GH and IGF-1 are mitogenic for some tumour types. Ipamorelin specifically has not been studied in cancer populations, but the mechanism is the same as exogenous HGH, which is contraindicated in active or recent cancer.

Treat as a relative contraindication for:

Active malignancy of any type
Recent (within ~5 years) malignancy of GH/IGF-1-responsive types — including breast, prostate, colon, and certain endocrine tumours
Multiple Endocrine Neoplasia syndromes
Strong family history of GH/IGF-1-responsive cancers, especially without screening in place

This is not a “definitely causes cancer” claim. It’s a “the mechanism is plausible enough that erring cautiously is the right call without specific evidence.” If you have a cancer history and are considering ipamorelin, get oncology input first.

Quality and sourcing

Standard research-chem caveats apply. No batch testing at point of sale, variable purity, occasional under-potency or contamination, no MHRA oversight. Vendors offering lab-test certificates (third-party mass spec) are a meaningful tier above those who don’t, but the certificates themselves can be falsified. Buying from vendors who are also mass-importing semaglutide and tirzepatide raises the floor on basic quality control because those compounds attract more scrutiny; small specialty vendors are more variable.

Populations where ipamorelin is contraindicated or high-risk

Active or recent cancer history (relative contraindication; see above)
Active acromegaly or known pituitary adenoma — ipamorelin can worsen GH-axis dysregulation
Pregnancy and breastfeeding — no safety data
Under 18 — endogenous GH is already at peak; no use case
Type 1 diabetes — GH antagonises insulin; affects glycaemic control without clear benefit
Severe insulin resistance / poorly-controlled type 2 diabetes — same concern, smaller margin
Active eating disorder (anorexia, bulimia, binge eating) — the morning hunger spike from ghrelin-receptor activation is the wrong direction
Sleep apnoea (untreated) — GH/IGF-1 effects on soft tissue may worsen airway collapse; treat the apnoea first

Measurement and dosing pitfalls

mg vs mcg confusion. 1 mg = 1,000 mcg. A “200” dose is 200 mcg, not 200 mg — that error would be a 1,000× overdose. The unit error is the most-reported reconstitution mistake.
Reading “units” as mg. 8 units on a U-100 syringe is 0.08 mL of solution, not 8 mg of compound.
Ignoring the fasted-dosing requirement. A non-fasted dose produces substantially less GH release. Users who report “ipamorelin doesn’t do anything for me” are sometimes describing a dosing-timing issue rather than a non-response.
Stacking with redundant GHRPs. Adding GHRP-2 or GHRP-6 to ipamorelin doesn’t increase the GH pulse meaningfully and removes ipamorelin’s selectivity advantage.

What the community gets wrong

“Anti-ageing peptide.” Mechanistically plausible only if you accept the chain “GH pulse → IGF-1 → favourable body composition → longevity benefit.” Each step is speculative for ipamorelin specifically. Not supported by outcome data.
“Like HGH but safer.” It produces a GH pulse, not sustained GH elevation. The effects are smaller than HGH and the safety profile is different (less risk of acromegaly-like changes; same theoretical IGF-1-driven cancer concerns).
“No side effects.” Most users tolerate it well, but water retention, mild carpal-tunnel-like paraesthesia, headache, and morning hunger are real and dose-dependent. “Minimal” is accurate; “none” is not.

FDA / regulatory status

Jurisdiction	Status	Last verified
US (FDA)	Compounding grey zone. Removed from Category 2 in September 2024; reviewed at the October 2024 PCAC meeting. February 2026 HHS announcement signalled a Category 1 reclassification was imminent, but as of late April 2026 the formal reclassification has not been published. Compounding pharmacies operate in regulatory uncertainty.	2026-04-29
UK (MHRA)	Not approved. No licensed product. Sold as a research chemical under the standard “research use only / not for human consumption” labelling convention, which permits sale of the raw peptide but does not authorise human use.	2026-04-29
EU (EMA)	Not approved. No licensed product.	2026-04-29
WADA (sport)	Prohibited. Listed under S2 (Peptide Hormones, Growth Factors, and Related Substances). In and out of competition.	2026-04-29

Narrative. Ipamorelin’s regulatory trajectory in the US is the most active of any GHRP — the pharmacy compounding pathway under 503A may legalise compounded ipamorelin if the Category 1 reclassification publishes. For UK readers, that pathway does not exist; the only legal access route remains research-chemical purchase, with the same legal grey area as the rest of this encyclopedia.

For athletes and any user considering competitive sport: ipamorelin is on the WADA prohibited list. Out-of-competition testing can detect it; the metabolites are detectable in urine for up to 24 hours post-administration, and pituitary GH-pulse signatures may be detectable for longer.2

What to track in Peptrax

Ipamorelin’s clinical signal is sleep, not body composition — the GH pulse it triggers is real and reproducible, but the downstream effects users actually care about (lean mass, recovery) are more variable than the bedtime sleep change is. The app’s job for ipamorelin users is making the sleep signal legible enough to decide whether to keep going.

For most users, the highest-signal log is subjective sleep quality and morning state: how rested you feel, how vivid the dreams were, how easily you woke. Ipamorelin’s most consistent community-reported effect is on sleep architecture, and a daily 1–5 rating of sleep depth across the first 4–8 weeks of a protocol is the cleanest read on whether the compound is doing anything for you specifically. Body composition changes, if they appear, take longer (8–12 weeks) and are harder to attribute given the other variables most users adjust simultaneously.

For sensitive-systems users, the higher-priority log is the first 2–3 weeks of dosing: any headache, water-retention symptoms (rings tighter, hands puffy, carpal-tunnel-like tingling), morning hunger spikes, blood-pressure changes. These are dose-dependent and reversible, but only if you noticed them. A clear written stop criterion — “if symptom X persists past day 5 at this dose, drop the dose” — is more useful than reconstructing one mid-flare.

Across all users, logging the stack composition matters: ipamorelin alone, ipamorelin + CJC-1295, dose ratio, time of injection relative to last meal. Ipamorelin’s response is timing-sensitive (fasted vs. fed makes a measurable difference) and stack-sensitive (the synergy with a GHRH analogue is the entire reason most users see results), so reconstructing what worked later requires the full setup, not just the dose. Vial reconstitution date matters because the 28-day stability window genuinely constrains the protocol.

For personal tracking and informational purposes only — not medical advice.